earli
diagnosi
acut
communityacquir
pneumonia
cap
import
patient
triag
treatment
decis
identifi
biomark
distinguish
patient
cap
noncap
control
conduct
untarget
global
metabolom
analysi
plasma
sampl
patient
cap
cap
case
without
cap
noncap
control
thirteen
lipid
metabolit
could
discrimin
cap
case
noncap
control
areaunderthereceiveroperatingcharacterist
curv
p
level
glycosphingolipid
sphingomyelin
lysophosphatidylcholin
lpalmitoylcarnitin
higher
level
lysophosphatidylethanolamin
lower
cap
case
noncap
control
metabolit
could
distinguish
cap
case
noninfect
extrapulmonari
infect
noncap
respiratori
tract
infect
subgroup
level
trihexosylceramid
higher
level
lysophosphatidylethanolamin
lower
fatal
nonfat
cap
case
find
suggest
lipid
metabolit
potenti
diagnost
prognost
biomark
cap
acut
communityacquir
pneumonia
cap
one
common
caus
hospit
death
musher
thorner
particular
emerg
viral
infect
includ
pandem
avian
influenza
virus
sar
mer
coronavirus
associ
mortal
rate
rang
chan
et
al
cheng
et
al
cheng
et
al
et
al
earli
recognit
treatment
cap
improv
outcom
li
et
al
musher
thorner
diagnosi
cap
depend
compat
symptom
sign
togeth
new
pulmonari
infiltr
chest
imag
musher
thorner
howev
distinguish
cap
pulmonari
patholog
difficult
wunderink
water
patient
cap
may
obviou
respiratori
symptom
noncap
caus
pulmonari
infiltr
chest
radiograph
mimic
due
cap
therefor
altern
modal
diagnos
cap
import
biomark
bodi
fluid
increasingli
use
determin
diagnosi
predict
prognosi
lung
diseas
upadhyay
niederman
wheelock
et
al
procalcitonin
sensit
biomark
bacteri
pneumonia
level
much
lower
pneumonia
caus
virus
atyp
bacteria
muller
et
al
upadhyay
niederman
adenosin
deaminas
use
biomark
tuberculosi
pleural
effus
chen
et
al
prognost
marker
includ
creactiv
protein
procalcitonin
midregion
proadrenomedullin
midregion
proatrial
natriuret
peptid
copeptin
precursor
kallistatin
cytokin
christcrain
opal
lin
et
al
metabolom
studi
global
strategi
detect
lowmolecular
weight
compon
wheelock
et
al
increasingli
use
identifi
biomark
associ
infect
langley
et
al
tam
use
metabolom
analysi
previous
identifi
metabolit
could
distinguish
patient
bacteremia
without
bacteremia
small
studi
involv
children
sever
pneumonia
plasma
urin
metabolit
found
significantli
differ
healthi
commun
control
laiaki
et
al
plasma
metabolit
abl
diagnost
microbiolog
infecti
diseas
discrimin
patient
tuberculosi
healthi
control
frediani
et
al
urin
metabolit
found
differ
patient
pneumococc
pneumonia
caus
pneumonia
slupski
et
al
metabol
profil
may
also
predict
prognosi
patient
cap
seymour
et
al
studi
use
metabolom
approach
identifi
biomark
differenti
patient
cap
without
cap
furthermor
determin
whether
biomark
predict
prognosi
patient
cap
studi
includ
patient
admit
queen
mari
hospit
hong
kong
archiv
plasma
sampl
collect
admiss
retriev
metabolom
studi
cap
case
hospit
adult
patient
year
radiolog
evid
consolid
within
hour
admiss
least
one
follow
symptom
cough
without
sputum
product
dyspnea
tachypnea
pleurit
chest
pain
plu
one
auscultatori
find
one
sign
infect
core
bodi
temperatur
shiver
leukocyt
count
muller
et
al
noncap
control
hospit
adult
patient
fulfil
inclus
criteria
case
includ
subgroup
noninfect
subgroup
consist
patient
without
clinic
evid
infect
extrapulmonari
infect
subgroup
consist
patient
infect
outsid
respiratori
tract
noncap
respiratori
tract
infect
subgroup
consist
patient
respiratori
tract
infect
without
radiolog
evid
pneumonia
patient
exclud
age
year
radiolog
evid
consolid
occur
day
hospit
admiss
clinic
record
access
review
archiv
plasma
sampl
avail
clinic
microbiolog
data
retriev
clinic
manag
system
pneumonia
sever
index
use
assess
clinic
sever
fine
et
al
fisher
exact
test
student
test
use
comparison
categor
continu
variabl
respect
studi
approv
institut
review
board
hkuha
hkw
irb
refer
number
uw
untarget
plasma
metabolom
profil
identif
metabolit
perform
describ
previous
modif
ultrahighperform
liquid
chromatographyelectrospray
ionizationquadrupol
timeofflight
mass
spectrometri
uhplcesiqtofm
analysi
use
identifi
metabolit
plasma
et
al
woo
et
al
detail
sampl
prepar
uhplcesiqtofm
identif
metabolit
provid
supplementari
inform
metabolom
data
analyz
report
accord
metabolom
standard
initi
http
msiworkgroupssourceforg
net
identifi
molecular
featur
mf
could
discrimin
cap
case
noncap
control
multivari
univari
analys
perform
multivari
analys
princip
compon
analysi
pca
partialleast
squar
discrimin
analysi
plsda
perform
unsupervis
supervis
analys
respect
univari
analysi
volcano
plot
construct
analyz
use
student
ttest
signific
mf
variabl
import
project
vip
score
plsda
volcano
plot
analysi
foldchang
p
valu
includ
univari
receiv
oper
characterist
roc
curv
analysi
signific
mf
areaundertheroc
curv
auc
identifi
boxwhisk
plot
gener
heatmap
base
signific
metabolit
construct
use
hierarch
cluster
analysi
hca
ident
signific
mf
character
total
patient
includ
studi
includ
cap
case
noncap
control
mean
age
year
statist
signific
differ
term
age
gender
inhospit
mortal
hospit
cap
case
noncap
control
tabl
differ
underli
diseas
except
chronic
lung
diseas
common
among
cap
case
vs
p
among
cap
case
commonli
identifi
respiratori
pathogen
haemophilu
influenza
n
streptococcu
pneumonia
n
tabl
blood
cultur
posit
patient
includ
patient
pneumonia
patient
escherichia
coli
patient
corynebacterium
speci
among
noncap
control
infect
extrapulmonari
infect
respiratori
tract
infect
without
evid
pneumonia
tabl
global
metabolom
determin
use
uhplcesiqtofm
total
mf
found
posit
neg
mode
respect
unsupervis
pca
without
bia
posit
mode
show
total
varianc
repres
first
princip
compon
supplementari
fig
pca
neg
mode
show
total
varianc
repres
first
princip
compon
supplementari
fig
pca
score
plot
mf
identifi
show
sampl
within
group
close
cluster
posit
neg
mode
supervis
plsda
score
plot
data
train
construct
select
mf
discrimin
cap
case
noncap
control
score
plot
posit
mode
show
accuraci
multipl
correl
coeffici
crossvalid
supplementari
fig
score
plot
neg
mode
show
accuraci
supplementari
fig
paramet
indic
optim
fit
predict
perform
plsda
model
ioniz
mode
detail
analysi
mf
use
volcano
plot
analysi
show
mf
posit
mode
mf
neg
mode
significantli
differ
cap
case
noncap
control
supplementari
fig
f
among
mf
mf
posit
mode
mf
neg
mode
vip
score
mf
manual
inspect
relat
interfer
includ
univari
roc
curv
analysi
univari
roc
curv
analysi
show
metabolit
auc
metabolit
identifi
acylcarnitin
sphingolipid
glycosphingolipid
sphingomyelin
glycerophospholipid
lysophosphatidylcholin
lysopc
lysophosphatidylethanolamin
lysop
supplementari
tabl
supplementari
fig
cap
case
higher
level
acylcarnitin
glycosphingolipid
lysopc
sphingomyelin
lower
level
lysop
noncap
control
fig
hca
differenti
metabolit
separ
cap
case
noncap
control
major
cluster
supplementari
fig
univari
roc
curv
analysi
show
lysopc
largest
auc
highest
sensit
specif
tabl
metabolit
compar
cap
case
control
subgroup
noninfect
subgroup
extrapulmonari
infect
subgroup
noncap
respiratori
tract
infect
subgroup
metabolit
significantli
differ
cap
case
subgroup
supplementari
fig
tabl
metabolit
also
compar
differ
subgroup
cap
case
level
trihexosylceramid
higher
fatal
case
nonfat
case
level
lysop
also
significantli
lower
cap
patient
psi
class
psi
class
level
metabolit
significantli
differ
cap
patient
bacteri
viralmycoplasma
pneumonia
p
n
metabolit
supplementari
fig
assess
whether
metabolit
biomark
pneumonia
caus
classic
pathogen
commonli
identifi
cap
case
seri
compar
cap
case
classic
pathogen
exclud
enterobacteriacea
glucos
nonferment
noncap
control
metabolit
remain
significantli
differ
noncap
control
patient
cap
due
classic
pathogen
tabl
lysopc
highest
auc
sensit
specif
studi
use
untarget
global
metabolom
approach
identifi
metabolit
high
sensit
high
specif
discrimin
cap
case
noncap
control
level
sphingolipid
glycosphingolipid
sphingomyelin
glycerophospholipid
lysopc
acylcarnitin
lpalmitoylcarnitin
higher
level
glycerophospholipid
lysop
fig
boxwhisk
plot
metabolit
distinguish
cap
case
noncap
control
horizont
line
repres
median
bottom
top
box
repres
percentil
whisker
repres
percentil
lower
cap
case
noncap
control
chang
plasma
lipid
metabolit
level
cap
patient
may
relat
sever
reason
firstli
lipid
make
surfact
disturb
surfact
pneumonia
may
caus
chang
lipid
metabol
wheelock
et
al
secondli
lipid
import
inflammatori
mediat
infect
chang
lipid
metabolit
observ
condit
sepsi
bacteremia
viral
infect
cui
et
al
langley
et
al
thirdli
lipid
import
structur
function
bacteria
lipid
metabolit
produc
bacteria
kondakova
et
al
therefor
futur
studi
biomark
discoveri
would
worthwhil
optim
extract
detect
step
find
lipid
metabolit
studi
lipid
metabolit
discrimin
cap
case
noncap
control
glycerophospholipid
lysopc
lysop
compon
pulmonari
surfact
import
modul
inflamm
makid
et
al
lysopc
highest
sensit
specif
level
lysopc
higher
cap
case
noncap
control
level
lysop
lower
cap
case
noncap
control
find
differ
patient
dengu
viru
infect
serum
lysopc
lysop
reduc
cui
et
al
high
level
lysopc
cap
patient
relat
specif
host
chang
pneumonia
high
plasma
level
lysopc
cap
patient
may
caus
releas
lysopc
surfact
lung
injuri
arbib
et
al
lysopc
may
also
contribut
direct
toxic
lung
grossmann
et
al
vlaar
et
al
zhou
et
al
howev
previou
studi
show
plasma
level
lysopc
lower
among
fatal
nonfat
patient
low
level
lysopc
postul
associ
dysregul
inflammatori
respons
cho
et
al
studi
plasma
level
lysopc
significantli
lower
highrisk
cap
case
also
lower
fatal
cap
case
nonfat
cap
case
although
reach
statist
signific
tabl
lack
statist
signific
may
relat
rel
small
number
fatal
case
cohort
studi
need
assess
whether
lysopc
favor
prognost
factor
hand
plasma
level
lysop
lower
cap
case
noncap
control
mous
periton
model
lysop
shown
increas
level
antiinflammatori
cytokin
reduc
plasma
leakag
hung
et
al
level
lysop
significantli
lower
fatal
cap
case
nonfat
cap
case
therefor
higher
lysop
level
cap
may
improv
surviv
via
amelior
excess
inflamm
studi
level
sphingolipid
higher
cap
case
noncap
control
sphingolipid
associ
mani
pulmonari
diseas
uhlig
gulbin
sphingolipid
critic
structur
function
plasma
membran
involv
mani
cellular
process
lactosylceramid
trihexosylceramid
tetrahexosylceramid
metabolit
ceramid
fig
ceramid
import
regul
immun
cell
tabl
auc
sensit
specif
roc
curv
calcul
optim
cutoff
well
vip
score
p
valu
foldchang
metabolit
distinguish
cap
case
noncap
control
metabolit
auc
ci
sensit
specif
vip
score
foldchang
b
p
valu
c
acylcarnitin
lpalmitoylcarnitin
auc
areaunderthereceiveroperatingcharacterist
curv
ci
confid
interv
lysopc
lysophosphatidylcholin
lysop
lysophosphatidylethanolamin
vip
variabl
import
project
vip
score
plsda
analys
b
fold
chang
cap
case
rel
noncap
control
indic
increas
level
indic
decreas
level
cap
case
compar
noncap
control
c
student
test
comparison
level
metabolit
fatal
n
nonfat
n
cap
case
patient
high
risk
class
n
low
risk
class
n
fold
differ
fatal
nonfat
cap
case
p
valu
fold
differ
high
risk
low
risk
cap
case
b
indic
level
higher
fatal
case
nonfat
case
indic
level
lower
fatal
case
nonfat
case
b
high
risk
pneumonia
sever
index
class
v
low
risk
pneumonia
sever
index
class
traffick
vascular
epitheli
integr
maceyka
spiegel
exampl
lactosylceramid
mediat
inflammatori
respons
trigger
pneumocysti
evan
et
al
vitro
influenza
viru
infect
induc
elev
level
hexosylceramid
tanner
et
al
inhibit
glycosphingolipid
synthesi
associ
reduc
pulmonari
inflamm
mice
challeng
lipopolysaccharid
lp
dechecchi
et
al
sphingomyelin
structur
compon
cell
membran
maceyka
spiegel
mice
sphingomyelin
synthas
catalyz
synthesi
sphingomyelin
activ
lpsinduc
lung
injuri
inhibit
attenu
lung
injuri
endotheli
barrier
disrupt
anjum
et
al
mice
studi
suggest
sphingomyelin
import
lung
injuri
higher
level
sphingomyelin
cap
case
compat
hypothesi
howev
studi
suggest
high
level
sphingomyelin
may
protect
stringer
et
al
show
patient
acut
lung
injuri
lower
level
sphingomyelin
compar
healthi
control
although
absolut
differ
small
stringer
et
al
level
lpalmitoylcarnitin
significantli
higher
cap
case
noncap
control
lpalmitoylcarnitin
facilit
transport
longchain
fatti
acid
cytoplasm
mitochondria
fatti
acid
betaoxid
take
place
acut
lung
injuri
fatti
acid
metabol
disturb
guo
et
al
previou
studi
also
show
high
level
lpalmitoylcarnitin
associ
poorer
prognosi
patient
chronic
heart
failur
ueland
et
al
studi
signific
differ
proport
patient
heart
diseas
metabol
pathway
interconnect
fig
fatti
acid
betaoxid
import
provid
substrat
gener
sphingolipid
glycerophospholipid
via
ceramid
phosphatid
acid
respect
ecker
liebisch
maceyka
spiegel
ceramid
convert
glucosylceramid
convert
lactosylceramid
phosphatid
acid
convert
diacylglyerol
convert
phosphatidylcholin
phosphatidylethanolamin
sphingolipid
pathway
also
connect
glycerophospholipid
pathway
via
sphingosin
kihara
maceyka
spiegel
sever
limit
studi
firstli
test
metabolom
profil
first
avail
plasma
sampl
patient
serial
monitor
metabolit
may
help
assess
diseas
progress
secondli
analyz
relationship
specif
pathogen
metabolit
limit
number
patient
infect
pathogen
thirdli
higher
proport
cap
case
underli
chronic
lung
diseas
noncap
control
previou
studi
show
level
plasma
serum
metabolit
differ
patient
chronic
lung
diseas
healthi
control
compar
healthi
control
patient
chronic
obstruct
pulmonari
diseas
higher
level
glycerophophocholin
lower
level
lipoprotein
amino
acid
patient
asthma
higher
level
taurin
lathosterol
bile
acid
nicotinamid
healthi
control
comhair
et
al
studi
requir
determin
whether
level
metabolit
identifi
studi
differ
patient
chronic
underli
diseas
healthi
control
fourthli
cohort
patient
noninfect
etiolog
lead
pulmonari
infiltr
interstiti
lung
diseas
studi
includ
patient
noninfect
pulmonari
diseas
without
evid
infect
detect
lowmolecularweight
molecul
increasingli
import
diagnosi
infect
use
global
metabolom
approach
identifi
lipid
metabolit
may
use
rapid
diagnost
prognost
biomark
cap
would
import
verifi
biomark
larger
cohort
differ
popul
furthermor
role
lipid
metabolit
pathogenesi
cap
deserv
studi
supplementari
data
articl
found
onlin
http
dx
